Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 3 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Phosphatidylcholine: regenerating the liver

Rachel Soon
Medical Writer
26 Jun 2018

We often take the health of our livers for granted. Unlike other organs such as the heart or the stomach, which make discrepancies known by various forms of acute physical discomfort, a gradual decline in liver function can often go unnoticed for years. In our July issue, in conjunction with World Hepatitis Day 2018, MIMS Pharmacist shines a Spotlight on phosphatidylcholine (PC) and the physiological role it plays in keeping the liver going.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 3 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.